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1.1	worldwide burden of dengue fever
	Nearly 4 billion people live in areas at risk of infection with dengue fever, a mosquito-borne viral disease that is frequently clinically inapparent yet linked to potentially lethal consequences. (1) Dengue is transmitted to humans from the bite of an Aedes mosquito, with symptoms typically presenting 4 to 7 days following the bite and somewhat similar to those of influenza: high fever, severe headache, pain behind the eyes, muscle and joint pain, and sometimes nausea and vomiting. In severe cases, the virus can progress to dengue shock syndrome (DSS) or dengue hemorrhagic fever (DHF), which can cause plasma leaking, respiratory distress, severe bleeding and even organ failure. Infants and children are particularly vulnerable to the effects of severe dengue, with some Asian and Latin American countries citing the virus as one of the leading causes of death among children. (2) There is no specific treatment for infection with any of the four serotypes of dengue (DENV-1, DENV-2, DENV-3 and DENV-4). However, the first vaccine was recently approved in Brazil, Mexico and the Philippines. The vaccine, Dengvaxia is only intended for use among individuals 9-45 years of age, but its development provides hope for a lower burden of the virus in the future. (3, 4)
	Recent evidence suggests that dengue is endemic in 128 countries, 36 of which were previously declared dengue-free. (5) Dengue transmission is highest in the tropics of the Americas and Asia, and an increased risk was found to be associated with high levels of precipitation, elevated temperatures, and urbanization. (1) An analysis of the 2013 Global Burden of Disease Study revealed a huge increase in the global incidence of dengue since 1990, with clinically apparent cases more than doubling each decade to reach a staggering 58.4 million in 2013. There was also a 58% increase in DALYs lost due to dengue between 1990 and 2013, increasing from 0.72 to 1.14 million. Yearly mortality estimates ranged from 8,000 to 10,000 deaths attributed to dengue, although the availability of data in the Global Burden of Disease Study was limited and the burden likely underestimated. 
	Geographically, the highest dengue incidence and mortality rates were found to be located in Southeast Asia. (6) Of the estimated 96 million symptomatic dengue infections in 2010, 70% occurred in Asia, 14% in the Americas and 16% of worldwide infections were localized to Africa. (1) The global burden of dengue continues to increase, posing a significant public health problem in terms of surveillance, vector control, and population dynamics- particularly in Southeast Asia. 
I was awarded a Fellowship to complete my MPH practicum at the University of Public Health in Yangon, Myanmar as part of an international modeling exchange initiative. Under the supervision of lecturers of epidemiology, I conducted a project to gain an understanding of the vector-borne disease surveillance system and the burden of dengue across provinces in Myanmar. 
1.2	dengue as an emerging problem in myanmar
	The tropical monsoon climate, increasingly mobile population and poor health infrastructure of Myanmar provides a thriving environment for the primary vector, Aedes aegypti mosquitoes and the rapid spread of dengue fever. The first DHF outbreak occurred in the former capital of Yangon in 1970, spreading to nearby areas including Bago Region, Mandalay Region, and Mon State in 1974. (7) By 2007, DHF was endemic in all 14 states of Myanmar except for Kayah State to the east, and Chin State in the northwest. Dengue is now also endemic in Kayah State while Chin remains the only state with no cases reported. Since the first outbreak, the incidence of DHF has increased 15-fold. (8) Besides the tropical climate and high urbanization, a high vulnerability to natural disasters in Myanmar exacerbates both the spread of dengue and scope of epidemics. Most recently, severe flooding swept through Myanmar from July to September of 2015, affecting 1 million people and worsening the already elevated risk of dengue infection and vector reproduction during monsoon season. (9)
The literature on the burden of dengue and DHF in Myanmar is limited. A study on the economic and disease burden in SE Asia in 2013 estimated the average annual economic burden of dengue to be $950 million US dollars. The cost associated with dengue in Myanmar was $0.30 per capita, with an estimated annual disease burden of 13,620 DALYs. (10) This average of annual DALYs lost due to dengue differed from a previous study conducted in 2000, in which yearly DALYs from dengue in Myanmar were 3,269. However, the much lower estimate of 3,269 annual DALYs lost can be attributed to the exclusive use of fatal and non-fatal DHF cases in the calculation, not including less severe forms of dengue. The lower average is also due to the use of data from 1970 to 1997, during which case reporting was much lower and the authors did not attempt to correct for underreporting. (11) Despite limited publications, it is clear that the overall economic and disease burden of dengue in Myanmar is increasing and presents challenges in the areas of surveillance, vector control and disaster response to be addressed and improved upon in the future.
	
1.3	Importance of regional surveillance
	Dengue surveillance is important for preparedness and disease control on both a global and local scale. Surveillance is a critical tool for public health activities such as detecting outbreaks, monitoring prevention programs and evaluating the efficacy of vaccination. Analyzing multi-country dengue surveillance data can provide valuable insight into the dynamics of disease transmission and pinpoint areas to target for Aedes control measures. Using province level dengue data from eight countries in SE Asia, researchers found a strong synchrony of dengue cycles across the region, increasing with high temperatures and decreasing at higher population densities. (12) This is just one example of how country surveillance data can be aggregated and used to benefit dengue research on a global scale.
There are numerous shortcomings and barriers to dengue surveillance, particularly in developing countries like Myanmar. Underreporting is a huge issue that results from a wide variety of factors such as lack of health staff, lack of motivation and leadership, and late or incomplete data analysis. (13) In an analysis of expansion factors for dengue cases in southeast Asia from 2001 to 2010, significant underreporting was found with only 13.2% of all symptomatic dengue cases reported to surveillance systems of different countries. (14) Most countries in SE Asia, including Myanmar, have passive surveillance systems for dengue reporting in which case counts depend on clinician reports during treatment, which fails to capture an accurate estimation of case numbers. In addition, underreporting is common until an epidemic is recognized, after which overreporting of cases often becomes an issue at the peak of the epidemic. (15) Accurate case counts and effective regional surveillance systems are integral to the estimation of the burden of dengue, an important measurement for policymakers and stakeholders to form conclusions about dengue control and prevention.
1.4	public health significance
	Dengue is becoming an area of concern in the public health field, and will likely continue to pose a threat as contributing factors like climate change, population dynamics and travel evolve in the future. 
The economic burden of dengue is enormous when taking into consideration the personnel costs, hospitalizations, control measures, and lost productivity due to illness. A recent study estimated the cost of dengue in Sri Lanka during the epidemic year 2012 to be 3.45 million USD, with the largest percentage made up of personnel costs for control programs and hospitalizations. (16) In Cambodia, overall costs were as high as 14 million USD during the 2008 epidemic, while in Singapore the economic impact from 2000 to 2009 was estimated to be between 0.85 billion and 1.15 billion USD.  ADDIN EN.CITE (17, 18) Worldwide, the total cost of dengue was estimated to be nearly 40 billion USD per year in 2011, presenting a huge economic burden overall. (19) The immense costs associated with dengue speak to the importance of prevention and control measures and successful vaccine implementation.
	Although dengue is widely considered to be a disease affecting only populations in tropical climates, dengue is spreading into new areas as the global climate changes and air travel and international trade increase. Aedes vectors are present in California, with the recent introduction of Ae. aegypti in multiple counties near Los Angeles and San Diego. The border areas of Texas and California are prone to dengue outbreaks as well due to the spillover of infected mosquitoes from Mexico and imported cases. The presence of vectors in previously inhospitable environments has also been noticed in Mexico. (20) The increased risk of dengue and spread of Aedes mosquitoes into new areas presents a huge threat to public health, requiring an influx of resources and adding to the economic burden for preparedness, surveillance and control programs.
1.5	objective
	The objective of this study was to analyze trends of DHF morbidity and mortality in Myanmar from 2004 to 2014, comparing the burden faced in different regions and years, as well as the seasonality within each year. Analysis across all states and regions will also determine if an association between latitude and the timing of yearly epidemic peaks exists. The results will be useful to improve vector control and prevention programs, aiding in vaccine approval decisions, and providing valuable data for further dengue studies in SE Asia and worldwide.
2.0 	methods
2.1	study population
	DHF morbidity and mortality data from 2000 to 2014 was acquired from the Myanmar Ministry of Health (MOH) Vector Borne Disease Control Unit (VBDC) in collaboration with the University of Public Health in Yangon, Myanmar. The case data obtained included monthly counts of DHF cases and deaths passively reported to the VBDC from health facilities in each of the 14 states and regions during the time period of 2004 to 2014. The data also included yearly totals of DHF cases and deaths from an earlier period of 2000 to 2004. 
2.2	surveillance system in myanmar
2.2.1	Data Reporting Methods and Organization
	DHF is a reportable disease as one of the Diseases Under National Surveillance (DUNS) in Myanmar. Cases and deaths are passively reported in all states and regions except Chin State, which is under surveillance for the presence of Aedes mosquitoes. The medium for DHF case reporting in Myanmar is largely paper- and phone-based at the township, district and regional levels. Daily record forms from each health facility include the name of the hospital, township, address, and the number of patients diagnosed. An electronic vector-borne disease surveillance system at the MOH VBDC unit has been in use since 2014 and was donated by the Japan International Cooperation Agency (JICA). Within the JICA system, an electronic patient record forms includes state, hospital, date, patient demographics, admission and discharge date, disease grade, diagnosis and the patient’s condition. Figure 1 depicts the flow of data reporting for DHF from the most basic health services level through each broader administrative level until data is received at the MOH. Cases detected at Sub Rural Health Centers are reported to the Station Health Unit, which reports to the Township Health Office, where staff members report cases to the State/Regional Health Office, and on to the Department of Public Health VBDC and the Department of Medical Service within the MOH. Feedback at each level is an integral part of the system to monitor data quality and coordinate epidemic response when required.


Figure 1. DHF Data Reporting System Flow Diagram
2.2.2	Changes in Case Definitions
Dengue case definitions have not remained constant throughout the years since the first cases were reported in the 1970s. In 1997 the WHO case definition for dengue (DF) included the presence of an acute febrile illness along with two or more of the following: headache, rash, retro-orbital pain, myalgia, arthralgia, haemorrhagic manifestations or leukopenia, and laboratory testing or similar time and place as other confirmed cases. DHF was characterized by all of the following symptoms: fever lasting 2 to 7 days, haemorrhagic tendencies, thrombocytopenia, and evidence of plasma leakage. The case definition for DSS included the presence of all DHF criteria as well as circulatory failure evidence: rapid and weak pulse, narrow pulse pressure, or age-defined hypotension, cold clammy skin and restlessness. (21)           
In 2009 the case definitions were revised to include levels of severity for dengue classification including dengue without warning signs, dengue with warning signs, and severe dengue. The criteria for dengue without warning signs include fever and two of the following: nausea and vomiting, rash, aches and pains, and leukopenia. Dengue with warning signs is defined as any of the aforementioned symptoms and abdominal pain or tenderness, persistent vomiting, clinical fluid accumulation, mucosal bleeding, lethargy or restlessness, liver enlargement greater than 2 cm, and an increase in HCT. Criteria for severe dengue include dengue with at least one of the following: severe plasma leakage leading to shock or fluid accumulation with respiratory distress, severe bleeding, or severe organ involvement. (22) The case definitions were modified from the 1997 version to increase sensitivity for the diagnosis of severe dengue. (23)

2.3	Data analysis
DHF surveillance data was acquired from the Myanmar MOH VBDC electronic JICA surveillance system. Incidence rates were calculated from the provided DHF case counts using yearly Myanmar population estimates from The United Nations Population Division World Population Prospects. Case fatality rates (CFRs) were estimated using the number of reported deaths and cases for each year. All descriptive epidemiological analyses were performed using STATA 13.1 and Excel. The map of Myanmar was generated by use of QGIS 2.14. Latitudes of each state or region were found through a Google Maps search of the coordinates of capitals for each state or region.
3.0 	results











Table 1. Total number of DHF cases reported, fatalities and estimated incidence rates in Myanmar, 2000-2014


















		     CFR: case fatality rate
		     * Calculated from yearly Myanmar population estimates in The UN Population Division World     		        Population Prospects
		     † Cases reported from January through June only.

The seasonal distribution of DHF cases is largely concentrated around the monsoon season in Myanmar of May through early October (Figure 2). An estimated 88% of total cases were reported during these six months. Case reporting was particularly low from January to March, the later months of the dry season. Between 2004 and 2013, DHF case counts were the highest during the month of July across all years, consisting of approximately 27% of all DHF cases reported.  The years with low case reporting were 2004, 2011 and 2012. Total DHF reporting was the lowest in 2011, with the July peak not as pronounced and only a slight decrease in cases reported into August and September.

Figure 2. Monthly distribution of total DHF cases reported in Myanmar, 2004-2014
	








Figure 3. Map of Myanmar with states and regions labelled

Total DHF case counts and deaths varied widely across the different states or regions in Myanmar (Table 2). All states or regions were affected by DHF except for Chin State, where no cases were reported. An overwhelming majority of case reporting during the 2004-2014 period occurred in Yangon, with 31,345 cases. Ayeyarwaddy region had the second highest DHF morbidity and mortality, with 17,721 cases and 200 deaths. Geographically, the states and regions with the highest number of cases and fatalities were located in central and southern Myanmar.





















           *Estimates from the 2014 Population and Housing Census of Myanmar.

DHF cases fluctuated greatly throughout the 11-year period of 2004 to early 2014, while peaking between the months of May and October consistently (Figure 4). Different states and regions appear to have peaked earlier or later than others some years. Mon State, Tanintharyi Region, and Kayin State, all located in southeastern Myanmar reach the peak number of cases earlier than more western areas of the country.  This pattern of regions in the southeast peaking earliest is best exemplified in 2007, 2012 and 2013.


Figure 4. Seasonal trends of reported DHF cases for each state or region of Myanmar, 2004-2014







Figure 5. Peak DHF epidemic months for each state or region organized by latitude, 2004-2013
4.0 	discussion
Surveillance data from the Myanmar MOH covering the period of 2004 to 2014 indicates an increasing burden of DHF with seasonal variation and fluctuations between years. The largest epidemics to date occurred in 2009 and 2013, although 2014 data was incomplete and could have surpassed these case counts. There appears to be an approximate cyclical pattern of 3 to 4 years. Although there has been an upward trend in the overall DHF burden, the proportion of deaths among cases has declined. The trend of decreasing CFRs from the earlier half of the period into more recent years could reflect improvements in the timeliness of diagnosis or access to treatment. However, interpreting the reasons for case fluctuations between years is difficult due to the multitude of possible contributing factors involved.
The seasonality of DHF in Myanmar and observed epidemic peaks during monsoon season are consistent with results of earlier studies conducted in bordering countries such as Laos, Thailand and Bangladesh.  ADDIN EN.CITE (24-26) Each of these countries has varying types of surveillance systems, and yet all report the highest number of cases during this 5-6 month period, supporting the correlation between climate and Ae. aegypti activity. Dengue outbreaks have been associated with high levels of rainfall, temperatures and humidity due to their influence on the vector. Heavy rainfall increases the number of potential breeding sites for Ae. aegypti, which can be any range of objects able to collect small amounts of water. (27) It is striking that the annual peak epidemic month for Myanmar as a whole was consistently July of each year. This information may be helpful to both MOH officials and local staff for preparedness and executing control measures during an epidemic. 
Geographical variation was exhibited within Myanmar when comparing the DHF burden between the 14 states or regions. Yangon Region, home to the former capital and largest city had the highest number of cases reported between 2004 and 2014 by far, followed by Ayeyarwaddy Region and Mandalay Region. The only state with no case reporting was Chin State because the cooler temperatures and high altitude are not hospitable to Ae. aegypti. In an earlier study comparing the weighted mean distribution of dengue/DHF in the different states and regions of Myanmar from 1996 to 2001, wide regional differences were found as well. Areas with the highest weighted cases were Yangon Region, Mon State, and Mandalay Region. Researchers also found yearly CFRs ranging from 0.97 to 4.16, which are substantially higher than CFRs we calculated from 2000 to 2014. (28) The higher CFRs in earlier years of case reporting could again indicate either an actual improvement in early case detection and treatment or an underreporting of cases. Regardless, it is important to determine which regions exhibit the highest DHF morbidity and mortality in order to effectively allocate resources and target interventions toward areas of greatest need.
Region-specific analysis of DHF cases also led us to the conclusion that although total case counts in Myanmar were the highest during July of each year, some states and regions consistently peaked earlier or later than others. To test the observation of states or regions in the south peaking before those in the north, we plotted the latitudes against each peak epidemic month across all years. On average, states or regions in the southern part of Myanmar appear to have peaked approximately one month earlier, in June than those in the northern part of the country. These findings are interesting because they could imply wave-like properties in the spread of DHF epidemics from south to north in Myanmar as well as bordering countries in SE Asia. The results could even suggest that epidemics in Myanmar are linked to dengue outbreaks in bordering Thailand, perhaps propagating from the country into South Myanmar. 
There is a huge gap in the scientific literature concerning the epidemiology and surveillance of dengue and DHF in Myanmar, particularly in recent years. In 1998 Khin Mon Mon et al. reported the seasonal and regional distribution of DHF cases in Myanmar but failed to include data on the monthly level. Similarly, Cho Min Naing et al. explored the burden and seasonality of dengue and DHF from 1996 to 2001, but did not make any inferences on factors contributing to differences in peak timing between regions. Aside from studies performed over a decade ago, there appears to be a real dearth of existing literature and current research in the field. 
The main limitation of these results lies in the quality of data received from the MOH JICA surveillance system. Underreporting of DHF cases is highly probable, particularly since the healthcare infrastructure in Myanmar is rather poor. Public hospitals are overcrowded, often lacking necessary equipment and with a country average of 0.6 physicians per 1,000 people, diagnoses are not always accurate. (29) Dengue is often underdiagnosed and labeled as undifferentiated fever, and sometimes patients are discharged before physicians realize the diagnosis was incorrect, excluding them from the case count. Cases are also reported without notation of any previous dengue infection or genetic factors that may contribute to DHF infection, which would be useful for future analysis. Another consideration when interpreting the data is the DHF case definition change implemented by the WHO in 2009, which is more sensitive than the 1997 guidelines. (23) An increase in number of reported cases from before and after 2009 could, therefore, be simply a reflection of the increased sensitivity of the surveillance system. Technological barriers should also be acknowledged, since the electronic surveillance system was not implemented until early 2014 the MOH VBDC likely suffered from occasional losses of data resulting in incomplete case counts. There are therefore a number of limitations to consider when interpreting the DHF case data reported from JICA.
Results from this analysis of trends in DHF case reporting in Myanmar are highly applicable to similar countries in SE Asia and important to the field of public health. Pinpointing areas of the country most severely affected by the virus and the identifying the timing of greatest impact can help policymakers and health officials make integral logistical decisions about public health programs for vector control and vaccination in the future. Further research should be conducted to look into differences in serotype distribution and the impact of weather predictors and population characteristics to cultivate a greater understanding of dengue dynamics and improve methods of decreasing the global burden of DHF.

bibliography
1.	Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al. The global distribution and burden of dengue. Nature. 2013;496(7446):504-7.2.	World Health Organization. Media centre: Dengue and severe dengue 2015 [3.	Dengvaxia, World's First Dengue Vaccine, Approved in Mexico: Sanofi Pasteur; 2015 [Available from: http://www.sanofipasteur.com/en/articles/dengvaxia-world-s-first-dengue-vaccine-approved-in-mexico.aspx.4.	White V. Sanofi Pasteur's Dengvaxia approved in the Philippines 2015 [Available from: http://www.europeanpharmaceuticalreview.com/37458/news/industry-news/sanofi-pasteurs-dengvaxia-approved-in-the-philippines/.5.	Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG, et al. Refining the Global Spatial Limits of Dengue Virus Transmission by Evidence-Based Consensus. PLoS Negl Trop Dis. 2012;6(8):e1760.6.	Stanaway JD, Shepard DS, Undurraga EA, Halasa YA, Coffeng LE, Brady OJ, et al. The global burden of dengue: an analysis from the Global Burden of Disease Study 2013. The Lancet Infectious Diseases.7.	Thaung U, Ming C, Thein M. Dengue haemorrhagic fever in Burma. Southeast Asian J Trop Med Public Health. 1975;6(4):580-91.8.	Lon KN. DF/DHF Prevention and Control Program 2015.9.	Mizzima. Flood victims vulnerable to dengue. Mizzima News [Internet]. 2015. Available from: http://mizzima.com/news-domestic/flood-victims-vulnerable-dengue-fever.10.	Shepard DS, Undurraga EA, Halasa YA. Economic and Disease Burden of Dengue in Southeast Asia. PLoS Negl Trop Dis. 2013;7(2):e2055.11.	Cho Min N. Assessment of dengue hemorrhagic fever in Myanmar. Southeast Asian J Trop Med Public Health. 2000;31(4):636-41.12.	van Panhuis WG, Choisy M, Xiong X, Chok NS, Akarasewi P, Iamsirithaworn S, et al. Region-wide synchrony and traveling waves of dengue across eight countries in Southeast Asia. Proceedings of the National Academy of Sciences. 2015;112(42):13069-74.13.	Runge-Ranzinger S, Horstick O, Marx M, Kroeger A. What does dengue disease surveillance contribute to predicting and detecting outbreaks and describing trends? Tropical Medicine & International Health. 2008;13(8):1022-41.14.	Undurraga EA, Halasa YA, Shepard DS. Use of Expansion Factors to Estimate the Burden of Dengue in Southeast Asia: A Systematic Analysis. PLoS Neglected Tropical Diseases. 2013;7(2):e2056.15.	Gubler DJ. Aedes aegypti and Aedes aegypti-Borne Disease Control in the 1990s: Top Down or Bottom Up. The American Journal of Tropical Medicine and Hygiene. 1989;40(6):571-8.16.	Thalagala N, Tissera H, Palihawadana P, Amarasinghe A, Ambagahawita A, Wilder-Smith A, et al. Costs of Dengue Control Activities and Hospitalizations in the Public Health Sector during an Epidemic Year in Urban Sri Lanka. PLoS Negl Trop Dis. 2016;10(2):e0004466.17.	Beaute J, Vong S. Cost and disease burden of dengue in Cambodia. BMC public health. 2010;10:521.18.	Carrasco LR, Lee LK, Lee VJ, Ooi EE, Shepard DS, Thein TL, et al. Economic Impact of Dengue Illness and the Cost-Effectiveness of Future Vaccination Programs in Singapore. PLoS Negl Trop Dis. 2011;5(12):e1426.19.	Selck FW, A AA, R BC. An Estimate of the Global Health Care and Lost Productivity Costs of Dengue. Vector-Borne and Zoonotic Diseases. 2014;14(11):824-6.20.	Fredericks AC, Fernandez-Sesma A. The Burden of Dengue and Chikungunya Worldwide: Implications for the Southern United States and California. Annals of Global Health.80(6):466-75.21.	World Helath Organization. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. Geneva, Switzerland 1997.22.	World Health Organization. Dengue: guidelines for diagnosis, treatment, prevention and control. Geneva 2009.23.	Narvaez F, Gutierrez G, PÈrez MA, Elizondo D, NuÒez A, Balmaseda A, et al. Evaluation of the Traditional and Revised WHO Classifications of Dengue Disease Severity. PLoS Negl Trop Dis. 2011;5(11):e1397.24.	Karim MN, Munshi SU, Anwar N, Alam MS. Climatic factors influencing dengue cases in Dhaka city: A model for dengue prediction. The Indian Journal of Medical Research. 2012;136(1):32-9.25.	Khampapongpane B, Lewis HC, Ketmayoon P, Phonekeo D, Somoulay V, Khamsing A, et al. National dengue surveillance in the Lao People's Democratic Republic, 2006–2012: epidemiological and laboratory findings. Western Pacific Surveillance and Response Journal : WPSAR. 2014;5(1):7-13.26.	Limkittikul K, Brett J, L'Azou M. Epidemiological Trends of Dengue Disease in Thailand (2000–2011): A Systematic Literature Review. PLoS Neglected Tropical Diseases. 2014;8(11):e3241.27.	Hii YL. Climate and Dengue Fever: Early warning based on temperature and rainfall. Umeå University 2012.28.	Cho Min N. Time-Series Analysis of Dengue Fever/Dengue Haemorrhagic Fever in Myanmar since 1991 WHO Dengue Bulletin. 2002;26:24-32.29.	World Development Indicators [Internet]. 2016. Available from: http://databank.worldbank.org/data/reports.aspx?source=2&country=MMR&series=&period=#.
2.	World Health Organization. Media centre: Dengue and severe dengue 2015 [
3.	Dengvaxia, World's First Dengue Vaccine, Approved in Mexico: Sanofi Pasteur; 2015 [Available from: http://www.sanofipasteur.com/en/articles/dengvaxia-world-s-first-dengue-vaccine-approved-in-mexico.aspx.
4.	White V. Sanofi Pasteur's Dengvaxia approved in the Philippines 2015 [Available from: http://www.europeanpharmaceuticalreview.com/37458/news/industry-news/sanofi-pasteurs-dengvaxia-approved-in-the-philippines/.
5.	Brady OJ, Gething PW, Bhatt S, Messina JP, Brownstein JS, Hoen AG, et al. Refining the Global Spatial Limits of Dengue Virus Transmission by Evidence-Based Consensus. PLoS Negl Trop Dis. 2012;6(8):e1760.
6.	Stanaway JD, Shepard DS, Undurraga EA, Halasa YA, Coffeng LE, Brady OJ, et al. The global burden of dengue: an analysis from the Global Burden of Disease Study 2013. The Lancet Infectious Diseases.
7.	Thaung U, Ming C, Thein M. Dengue haemorrhagic fever in Burma. Southeast Asian J Trop Med Public Health. 1975;6(4):580-91.
8.	Lon KN. DF/DHF Prevention and Control Program 2015.
9.	Mizzima. Flood victims vulnerable to dengue. Mizzima News [Internet]. 2015. Available from: http://mizzima.com/news-domestic/flood-victims-vulnerable-dengue-fever.
10.	Shepard DS, Undurraga EA, Halasa YA. Economic and Disease Burden of Dengue in Southeast Asia. PLoS Negl Trop Dis. 2013;7(2):e2055.
11.	Cho Min N. Assessment of dengue hemorrhagic fever in Myanmar. Southeast Asian J Trop Med Public Health. 2000;31(4):636-41.
12.	van Panhuis WG, Choisy M, Xiong X, Chok NS, Akarasewi P, Iamsirithaworn S, et al. Region-wide synchrony and traveling waves of dengue across eight countries in Southeast Asia. Proceedings of the National Academy of Sciences. 2015;112(42):13069-74.
13.	Runge-Ranzinger S, Horstick O, Marx M, Kroeger A. What does dengue disease surveillance contribute to predicting and detecting outbreaks and describing trends? Tropical Medicine & International Health. 2008;13(8):1022-41.
14.	Undurraga EA, Halasa YA, Shepard DS. Use of Expansion Factors to Estimate the Burden of Dengue in Southeast Asia: A Systematic Analysis. PLoS Neglected Tropical Diseases. 2013;7(2):e2056.
15.	Gubler DJ. Aedes aegypti and Aedes aegypti-Borne Disease Control in the 1990s: Top Down or Bottom Up. The American Journal of Tropical Medicine and Hygiene. 1989;40(6):571-8.
16.	Thalagala N, Tissera H, Palihawadana P, Amarasinghe A, Ambagahawita A, Wilder-Smith A, et al. Costs of Dengue Control Activities and Hospitalizations in the Public Health Sector during an Epidemic Year in Urban Sri Lanka. PLoS Negl Trop Dis. 2016;10(2):e0004466.
17.	Beaute J, Vong S. Cost and disease burden of dengue in Cambodia. BMC public health. 2010;10:521.
18.	Carrasco LR, Lee LK, Lee VJ, Ooi EE, Shepard DS, Thein TL, et al. Economic Impact of Dengue Illness and the Cost-Effectiveness of Future Vaccination Programs in Singapore. PLoS Negl Trop Dis. 2011;5(12):e1426.
19.	Selck FW, A AA, R BC. An Estimate of the Global Health Care and Lost Productivity Costs of Dengue. Vector-Borne and Zoonotic Diseases. 2014;14(11):824-6.
20.	Fredericks AC, Fernandez-Sesma A. The Burden of Dengue and Chikungunya Worldwide: Implications for the Southern United States and California. Annals of Global Health.80(6):466-75.
21.	World Helath Organization. Dengue haemorrhagic fever: diagnosis, treatment, prevention and control. Geneva, Switzerland 1997.
22.	World Health Organization. Dengue: guidelines for diagnosis, treatment, prevention and control. Geneva 2009.
23.	Narvaez F, Gutierrez G, PÈrez MA, Elizondo D, NuÒez A, Balmaseda A, et al. Evaluation of the Traditional and Revised WHO Classifications of Dengue Disease Severity. PLoS Negl Trop Dis. 2011;5(11):e1397.
24.	Karim MN, Munshi SU, Anwar N, Alam MS. Climatic factors influencing dengue cases in Dhaka city: A model for dengue prediction. The Indian Journal of Medical Research. 2012;136(1):32-9.
25.	Khampapongpane B, Lewis HC, Ketmayoon P, Phonekeo D, Somoulay V, Khamsing A, et al. National dengue surveillance in the Lao People's Democratic Republic, 2006–2012: epidemiological and laboratory findings. Western Pacific Surveillance and Response Journal : WPSAR. 2014;5(1):7-13.
26.	Limkittikul K, Brett J, L'Azou M. Epidemiological Trends of Dengue Disease in Thailand (2000–2011): A Systematic Literature Review. PLoS Neglected Tropical Diseases. 2014;8(11):e3241.
27.	Hii YL. Climate and Dengue Fever: Early warning based on temperature and rainfall. Umeå University 2012.
28.	Cho Min N. Time-Series Analysis of Dengue Fever/Dengue Haemorrhagic Fever in Myanmar since 1991 WHO Dengue Bulletin. 2002;26:24-32.
29.	World Development Indicators [Internet]. 2016. Available from: http://databank.worldbank.org/data/reports.aspx?source=2&country=MMR&series=&period=#.























Submitted to the Graduate Faculty of
the Department of Epidemiology
Graduate School of Public Health in partial fulfillment 
of the requirements for the degree of





























Clareann H. Bunker, PhD               		______________________________________
Associate Professor
Department of Epidemiology




Willem van Panhuis, MD, PhD		______________________________________
Assistant Professor
Department of Epidemiology
Graduate School of Public Health
University of Pittsburgh

Essay Reader:                                                
Peter Veldkamp, MD, MSc                            ______________________________________
Associate Professor of Medicine





Copyright © by Ashley D. Vineyard
2016

Clareann H. Bunker, PhD

SPATIAL AND TEMPORAL TRENDS OF DENGUE HEMORRHAGIC FEVER IN MYANMAR FROM 2004 TO 2014
Ashley D. Vineyard, MPH
University of Pittsburgh, 2016




	ix


